UCSF

UC San Francisco Previously Published Works

Title

Volume of Distribution is Unaffected by Metabolic Drug-Drug Interactions

Permalink https://escholarship.org/uc/item/51k6f1r8

Journal Clinical Pharmacokinetics, 60(2)

ISSN

0312-5963

Authors

Sodhi, Jasleen K Huang, Caroline H Benet, Leslie Z

Publication Date 2021-02-01

DOI 10.1007/s40262-020-00926-7

 $Peer \ reviewed$

Volume of Distribution is Unaffected by Metabolic Drug-Drug Interactions

Jasleen K. Sodhi¹, Caroline H. Huang¹, Leslie Z. Benet¹

¹ Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California San Francisco, San Francisco, California

Corresponding Author: Leslie Z. Benet, 513 Parnassus Ave Rm HSE 1164, UCSF Box 0912, San Francisco, CA 94143; phone 415 476 3853; email leslie.benet@ucsf.edu

ORCID iD: Jasleen K. Sodhi: 0000-0001-6187-5597 Leslie Z. Benet: 0000-0002-9678-2371 Target Journal: Clinical Pharmacokinetics Article Type: Original Research Article Abstract Word Count: 252 / 250 Word Count: 3316 / 4000 Tables: 7 Figures: 2 References: 45

Running Title: 54 /100 Characters: Volume of Distribution is Unchanged for Metabolic DDIs

Abbreviation List:

AUC, area under the curve; AUMC, area under the moment curve; BDDCS, Biopharmaceutics Drug Disposition Classification System; *CL*, clearance; *CL/F*, apparent clearance; CYP, cytochrome P450; DDI, drug-drug interaction; EM, extensive metabolizers; *F*, bioavailability; IV, intravenous; *MIT*, mean input time; *MRT*, mean residence time; PK, pharmacokinetics; PM, poor metabolizers; τ , dosing interval; $t_{1/2,z}$, terminal half-life; V_{ss} , volume of distribution at steady-state; V_z , terminal volume of distribution; V_1 , initial volume of distribution in the central compartment; V_{ss}/F , apparent volume of distribution at steady-state

ABSTRACT (248 of 250 words)

It has been recognized that significant transporter interactions result in volume of distribution changes in addition to potential changes in clearance (CL). For drugs that are not clinically significant transporter substrates, it is expected that drug-drug interactions (DDIs) would not result in any changes in volume of distribution. An evaluation of this hypothesis proceeded via an extensive analysis of published intravenous (IV) metabolic DDIs, based on clinically recommended index substrates and inhibitors of major cytochrome P450 (CYP) isoforms. Seventy-two metabolic drug interaction studies were identified where volume of distribution at steady-state (V_{ss}) values were available for the CYP index substrates caffeine (CYP1A2), metoprolol (CYP2D6), midazolam (CYP3A4), theophylline (CYP1A2), and tolbutamide (CYP2C9). Changes in exposure (AUC) up to 5.1-fold were observed, however ratios of V_{ss} changes only ranged from 0.70 – 1.26, with one outlier displaying a V_{ss} ratio of 0.57. These results support the widely-held founding tenant of pharmacokinetics that CL and V_{ss} are independent parameters. Knowledge that V_{ss} is unchanged in metabolic DDIs can be helpful in discriminating changes in CL from changes in bioavailability (F) when only oral dosing data are available, as we have recently demonstrated. Since V_{ss} remains unchanged for IV metabolic DDIs, following oral dosing changes in V_{ss}/F will reflect changes in F alone. This estimation of F change can subsequently be utilized to assess changes in *CL* alone from calculations of CL/F. Utilization of this simple methodology for orally dosed drugs will have a

significant impact on how DDIs are interpreted from drug development and regulatory perspectives.

KEY POINTS

- While it is expected that significant xenobiotic transporter interactions will result in volume of distribution changes of victim drug, metabolic drug interaction should not result in any volume of distribution changes
- Evaluation of exemplary metabolic drug-drug interactions with clinically recommended index substrates and inhibitors indicates that volume of distribution is largely unchanged in metabolic interactions, highlighting that volume and clearance are indeed independent parameters
- Understanding that metabolic interactions do not result in volume changes can allow for estimation of bioavailability changes in oral drug-drug interactions. Examination of extent of change in apparent volume of distribution (V_{ss}/F) will reflect changes in bioavailability (F) alone due to unchanged V_{ss}
- Estimates of changes in *F* can subsequently be utilized to differentiate changes in clearance alone from measures of apparent clearance (*CL*/*F*) following oral dosing, as we have recently demonstrated [3]

1. INTRODUCTION

Volume of distribution in pharmacokinetics (PK) is the theoretical volume in which a drug must distribute to relate the observed systemic drug concentrations to the amount of drug present in the body. It is a nonphysiologic volume that reflects the degree of tissue distribution of drug. It has been recognized that xenobiotic transporters can influence the volume of distribution of drugs by allowing or restricting drug access to various tissues throughout the body [1], and therefore significant transporter drug interactions may result in changes in volume of distribution in addition to potential changes in clearance [2]. For drugs that are not clinically significant transporter substrates, it is expected that drug-drug interactions (DDIs) would not result in any changes in steady-state volume of distribution (V_{ss}) . As our laboratory has recently demonstrated, knowledge that V_{ss} is unchanged in metabolic DDIs can be helpful in implicating transporter involvement in complex DDIs as well as in facilitating the discrimination of changes in clearance from changes in bioavailability when only oral dosing data are available [3]. Here we present a comprehensive evaluation of the hypothesis that V_{ss} remains unchanged in metabolic drug interaction studies.

2. METHODS

2.1 Literature Search Strategy and Inclusion/Exclusion Criteria

Based on a recent compilation of recommended clinical index substrates of major drug metabolizing enzymes and cytochrome P450 (CYP) isoforms [4], a

comprehensive literature search identified caffeine (CYP1A2), metoprolol (CYP2D6), midazolam (CYP3A4), theophylline (CYP1A2) and tolbutamide (CYP2C9) as index substrates for which intravenous (IV) dosing drug interaction data were available. Oral drug interaction studies of these index substrates were excluded from the analysis to avoid the confounding impact that changes in bioavailability (F) would have on apparent volume of distribution (V_{ss}/F). Due to the large number of IV interaction studies for the probe substrate midazolam, the scope of the analysis was further refined to primarily include DDIs involving index inhibitors with known clinical inhibitory specificities against the various CYP isoforms and xenobiotic transporters, again based on the recent recommendations of Tornio et al. [4]. If additional victim-perpetrator combinations were investigated in these studies, these interaction data were also included in the analysis and information regarding the *in vivo* substrate or inhibitory specificities of these drugs were referenced from the literature [5-11]. Since V_{ss} is not often reported by clinical investigators, estimation of this parameter often proceeded via digitization and non-compartmental analysis of published pharmacokinetic profiles. If V_{ss} was not reported, studies were excluded if (1) pharmacokinetic profiles were not reported and/or were difficult to reliably digitize, or if (2) resulting estimates of AUC were greater than 25% different from reported values. The latter aspect will be further discussed in the next section.

This analysis focuses on DDI studies conducted with the same subjects in the control and treatment arms, and as such, four midazolam studies with

a parallel study design were excluded. However, some studies included in this analysis conducted the DDI investigation (within the same person) in multiple populations, for example, with respect to pharmacogenomic variance of drug metabolizing enzymes or in healthy versus disease state subjects. Thus, we also analyze changes in V_{ss} of victim drug only between these populations to investigate the inherent potential of V_{ss} to change between different individuals.

The specificities of all substrates and inhibitors are summarized, and in addition, the Biopharmaceutics Drug Disposition Classification System (BDDCS) is listed. This simple system classifies drugs based on solubility and permeability and can anticipate when metabolism versus transportermediated processes (such as renal and biliary elimination) are the major route of drug elimination [12].

2.2 Data Analyses

Thirty published DDI studies were examined and changes in exposure (*AUC*), clearance (*CL*), V_{ss} , mean residence time (*MRT*) and terminal half-life ($t_{1/2,z}$) were calculated and reported as ratios of interaction/control. When individual PK data were reported, the ratios of the parameters-of-interest were calculated for each individual and the average of this ratio for all subjects was reported (and indicated in tables with a footnote). Although initial volume of distribution in the central compartment (V_1) and terminal volume of distribution (V_2) are commonly reported in clinical pharmacokinetic

studies, our primary analysis was based on changes in V_{ss} as it is a noncompartmental parameter that represents the whole-body volume of distribution, theoretically is independent of elimination measures [13], and is not associated with a particular compartment or phase of the PK curve (as is the case for V_I and V_z for drugs that display multi-compartment kinetics). Methods of each paper were carefully reviewed to ensure reported V_{ss} was appropriately calculated. For investigations in which V_{ss} could not be determined, data for V_z were reported with the understanding that V_z changes will only reflect the same degree of change as V_{ss} if the victim drug follows a one compartment model or if the distribution phase minimally affects measures of both *AUC* and *AUMC* (area under the moment curve).

For investigations that did not explicitly report all parameters-ofinterest, the parameter was either (1) back-calculated from reported data or (2) estimated by digitization of reported plasma-concentration time profiles. Clearance and AUC could be calculated from one another if only one of the two parameters were reported by using known dose and the equation: CL =*Dose / AUC*. Similarly, *CL* can be used to calculate either *V*_{ss} or *MRT* (if one of the two parameters were reported) using Eq. 1[13]:

$$V_{ss} = CL \bullet MRT$$
 (Eq. 1)

If *MRT* values were not reported, *MRT* was calculated via non-compartmental methods by Eq. 2:

$$MRT = \frac{AUMC}{AUC} - MIT$$
(Eq. 2)

where MIT is mean input time. For IV bolus doses, MIT is zero. For IV infusions, *MIT* is defined as half of the length of the dosing interval (τ) , i.e. $MIT = \tau / 2$. For investigations that did not report V_{ss} (or any of the other pharmacokinetic parameters of interest), plasma concentration-time profiles were digitized using WebPlotDigitizer Version 4.2 (San Francisco, CA) and analyzed by non-compartmental analysis with WinNonlin Professional Edition Version 2.1 (Pharsight, Mountain View, CA). Digitized AUC values were compared to reported AUC values and studies were excluded if reported average AUC values were greater than 25% different from digitized values. All pharmacokinetic ratios calculated from digitization of published concentration-time profiles are specifically indicated in the data tables with a footnote. Published values of pharmacokinetic parameters were reported in priority, with digitization/reanalysis of reported average concentration-time profiles utilized only to supplement unreported data. Each value in the data tables is annotated based on calculation methods (published versus digitized, individual versus average PK data used for ratios, equations used or assumptions made).

The average absolute difference in AUC and V_{ss} were compared to one another for all 72 DDIs, as well as the subset of DDIs with greater than 30% AUC change (i.e. ratios outside of the range of 0.77 and 1.30, n=49), which

could be considered a potentially clinically significant interaction. To account for interactions resulting in a decrease in *AUC*, such as potential enzyme induction, the inverse for all ratios less than unity was utilized in calculation of average absolute *AUC* and V_{ss} changes. Box plot representations of the data were generated to allow visual depiction of any differences in degree of change in these two parameters, which indicate the median, 25th and 75th percentiles, range from minimum to maximum values, and depict each individual point. To investigate if the classic trend of *CL* changes being equal (but opposite in magnitude) to half-life and *MRT* changes in these metabolic DDIs, the relationship between changes in half-life and *MRT* were compared to the inverse of the change in *CL*.

3. RESULTS

Relevant information on the specificity of all substrates analyzed are outlined in Table 1 and the inhibitory specificities of the perpetrator drugs included in this analysis are listed in Table 2. The comprehensive literature search identified DDI studies for the following index substrates where V_{ss} measurements were available: caffeine [14], metoprolol [15], midazolam [16-25], theophylline [26-38], and tolbutamide [39] (Table 3). Any additional victim-perpetrator combinations (with non-index substrates) investigated in these studies where V_{ss} measurements were available were also analyzed, including alfentanil [20], antipyrine [27], and lidocaine [19] (Table 4). When only V_z values were available, these studies are summarized in Table 5 and include the victim drugs antipyrine [40], desipramine [41], imipramine [41], and theophylline [40, 42-44].

The changes in pharmacokinetic parameters (*AUC*, *CL*, *V*_{ss}, *MRT* and $t_{1/2,z}$) of clinically recommended index substrates are listed in Table 3 and additional victim drugs in Table 4, totaling 72 DDI studies. For these primarily metabolized drugs, *AUC* ratios ranged from 0.44 - 5.1 while *V*_{ss} ranged from 0.57 - 1.40. The average absolute difference in *AUC* ratios for these 72 DDI studies averaged 1.69 ± 0.78, while the average absolute difference in *V*_{ss} averaged 1.10 ± 0.12. For the 49 interactions with at least a 30% change, i.e., those interactions that could potentially be clinically significant, the absolute *AUC* changes averaged 1.95 ± 0.83, while *V*_{ss} averaged 1.11 ± 0.13. Figure 1 depicts box plot representations of these values. Of the 72 DDI studies examined, only three (4.2%) resulted in greater than a 30% change in *V*_{ss} (i.e. ratios outside of the range of 0.77 to 1.30) with ratios of 0.70 [15], 1.40 [18] and 0.57 [24].

An additional 10 DDI studies were identified from 5 studies for which only V_z was reported and V_{ss} could not be determined (due to lack of published PK profiles) (Table 5). Changes in *AUC* ranged from 1.10 – 1.70, but V_z only ranged from 0.89 – 1.24.

While the inclusion criteria of this analysis focused on studies that include the same patients in the control and interaction phases, three DDI studies investigated here performed the same drug interaction study in multiple groups, either with respect to pharmacogenomic variance of

metabolizing enzyme [15, 21] or disease state [28]. To investigate the impact of inter-individual variability on V_{ss} , the control phase (victim drug only) between each group were compared to one another (Table 6). When comparing the PK of the index substrate alone between groups, V_{ss} for victim drug was observed to change with ratios of 0.51 (metoprolol with CYP2D6 and 0.79 (midazolam pharmacogenomics), 0.72 with CYP3A5 pharmacogenomics), and 0.70 (healthy versus liver cirrhosis patients), while AUC was observed to change 0.98- to 2.56-fold in these studies. In the same studies, however, minimal change in V_{ss} was observed in the same individual between the drug interaction versus control phases, with ratios ranging from 0.70 - 1.13 (Table 3).

4. DISCUSSION

For primarily metabolized drugs, IV drug interaction studies resulted in minimal changes to V_{ss} . Changes in drug exposure (*AUC*) up to 5.1-fold were observed, however ratios of V_{ss} changes only ranged from 0.70 – 1.40, with one outlier displaying a 43% decrease in V_{ss} (ratio of 0.57) (Table 3) for a midazolam-ketoconazole interaction in healthy female Koreans where the *AUC* ratio was 4.61 [24]. In contrast, a second midazolam-ketoconazole interaction study in healthy White subjects with a similar *AUC* ratio of 5.1 only exhibited a V_{ss} ratio of 1.20 [23]. The trend of unchanged V_{ss} was observed for all index substrates and CYP isoforms investigated (caffeine and

theophylline, CYP1A2; metoprolol, CYP2D6; tolbutamide, CYP2C9; midazolam, CYP3A4) (data not shown).

It should be noted that a listed high percent *AUC* extrapolation value does not necessarily indicate that *AUC* (or PK parameters derived from *AUC*) are unreliable if the slope of the elimination phase is adequately captured. Additionally, the pharmacokinetic parameters reported by the original authors were used in priority to calculate the ratios presented in this analysis, such as the frequently reported parameters *AUC*, *CL* and $t_{1/2,z}$. Estimation of less-frequently reported parameters, such as V_{ss} and *MRT*, proceeded via digitization of the average concentration-time profiles reported by the original authors, and it should be noted that these average profiles may not accurately represent changes within any one particular individual in the DDI study.

When V_{ss} was not reported (and could not be calculated due to the lack of published PK curves), changes in V_z were examined (Table 5). Changes in V_z were minimal (0.89 – 1.24). Examination of theophylline PK curves from the other studies in this analysis indicate that the distribution phase of theophylline is very short, and therefore V_z changes would likely be similar to V_{ss} changes. No such conclusions related to the potential similarity between V_z and V_{ss} could be made for the antipyrine, desipramine or imipramine data due to the lack of published IV pharmacokinetic curves in the other studies examined here.

Of note, the clinical studies included in this analysis were all conducted with the same individuals in the control versus interaction arms, to minimize the confounding effects of inter-individual variability. Three of the studies examined here also conducted DDIs in multiple subject groups with respect to disease state [28] or pharmacogenomic variance of drug metabolizing enzyme [15, 21]. To examine the potential impact of inter-individual differences in V_{ss} , the pharmacokinetic parameters associated with the control arms (victim drug only) of each group were compared to one another, resulting in V_{ss} ratios of 0.51 – 0.79 associated with AUC changes of 0.98 – 2.56 (Table 6). In comparison to the earlier part of this analysis where changes in V_{ss} within the same individual (with and without addition of a perpetrator drug) were examined, these same studies displayed V_{ss} ratios of 0.70 - 1.26 associated with AUC increases of 1.12 - 3.08. Reported data related to the body weights of individuals in each arm are also noted in Table 5. However accounting for average differences in body weight between the two groups does not necessarily result in V_{ss} ratios that are closer to unity. For instance, the reported differences in metoprolol V_{ss} between CYP2D6 poor metabolizers (PM) and extensive metabolizers (EM) resulted in a ratio of 0.51, and the reported values used to calculate this ratio were normalized by body weight of each individual by the original investigators. This indicates that volume of distribution differences in different individuals can be significant and do not only depend on total body weight differences. Further, the variability associated with V_{ss} values was much greater in EM than PM,

with CV values of 44% and 22%, respectively. The issue of variability between individuals is further compounded in pharmacogenomic studies where often only a very small number of individuals can be recruited for the less frequently occurring genotypes.

This highlights that for the same drug, V_{ss} may change significantly between subjects. These findings are in contradiction to the belief that all pharmacokinetic parameters are expected to be similar in homogenous populations, such as in healthy subjects, since the pharmacogenomic interactions studied here included healthy subjects in each arm. As a result, we suggest that it may not appropriate to assume that V_{ss} is unchanged across different subject populations and therefore, it is crucial to consider clinical study design (parallel versus crossover). Further, based on this that examination of observation we emphasize differences in pharmacokinetics in different pharmacogenomic variance or disease state populations should be considered as a qualitative outcome. Although changes in AUC and CL can reasonably be compared between groups, however, since V_{ss} may inherently be different between individuals in each group, changes in terminal half-life should not be considered significant nor be utilized to suggest changes in dosing regimen between the two populations studied. Further investigation into this finding is warranted, and is an area of high interest to our laboratory.

It should be noted that perpetrator drugs have the potential to displace victim drug from plasma or tissue binding sites, which may result in V_{ss}

changes. From Eq. 1, changes in protein binding should result in comparable changes for *CL* and V_{ss} with no change in *MRT* or half-life. However, we find no examples of such an interaction in the same subjects within our dataset. Thus, the data presented here presented here for IV metabolic drug interaction studies very strongly support our contention that V_{ss} does not change to any significant degree for metabolic DDIs.

The DDI studies evaluated here follow the classic pharmacokinetic trend of changes in CL resulting in an equal but opposite change in MRT, due to the fact that V_{ss} remains unchanged for metabolic interactions (Eq. 1) [45]. These relationships are depicted in Figure 3, where the inverse of ratios of CL changes are plotted against both *MRT* and $t_{1/2,z}$ ratios. The results for each comparison fall very close to the line of unity, highlighting the intuitive trend that decreases in clearance result in increases in MRT and $t_{1/2,z}$ of approximately equal magnitude. In comparing the AUC-MRT relationship to the AUC- $t_{1/2,z}$ relationship, as expected the MRT relationship falls closer to the line of unity than a few of the $t_{1/2,z}$ points associated with larger 1/CL ratios, as $t_{1/2,z}$ may change differently than MRT for drugs that display multicompartment kinetics, and this difference is likely amplified in DDI studies of larger magnitude. In general, Figure 3 highlights that changes in clearance are opposite in direction but similar in magnitude to MRT and $t_{1/2,z}$ and this is in sharp contrast to significant transporter-drug interactions, where decreases in CL can often be associated with decreases in half-life and MRT, due to changes in V_{ss} [2].

As our laboratory has recently presented, knowledge that V_{ss} remains unchanged in metabolic DDI studies can facilitate estimation of changes in clearance from changes in bioavailability following an oral dose [3]. In the Quinney et al. [17] study of the interaction of midazolam and clarithromycin in elderly subjects, the interaction was conducted following both oral and IV dosed midazolam. Thus, estimates of changes in CL versus F based on the oral interaction study can be confirmed by examining the observed changes resulting from the IV midazolam interaction study. Following oral dosing, an 8.2-fold increase in midazolam exposure was observed (compared to only a 3.2-fold increase in midazolam AUC in the IV drug interaction study) when clarithromycin was dosed 500 mg BID for 7 days (Table 7). Knowing that V_{ss} largely remains unchanged for IV metabolic DDIs (based on the analysis presented here) supports the assumption that changes in V_{ss}/F following an oral dose will reflect changes in F alone. This estimation of F change can subsequently be utilized to assess changes in CL alone from calculations of CL/F [3]. Utilizing this methodology, the predicted increase in bioavailability was 2.84-fold and CL was predicted to decrease by 60% (ratio of 0.40), compared to the observed 2.12-fold increase in bioavailability and 65% reduction of *CL* (ratio of 0.35) (Table 7). Thus, recognition that V_{ss} remains unchanged in metabolic interactions allows discrimination of two PK parameters thought to be indistinguishable from one another following oral dosing.

5. CONCLUSIONS

Based on an extensive evaluation of 72 clinical DDI studies, V_{ss} remains unchanged for IV metabolic drug interactions as expected, with a small minority of outliers (only 3) with ratios indicating a change, where for the largest V_{ss} change, a second study of the same interacting drugs in a different population did not show this marked V_{ss} change. These results uphold the widely-held founding tenant of pharmacokinetics that CL and V_{ss} are independent parameters. Differences in victim drug V_{ss} can significantly vary throughout the population due to inter-individual variability that may not necessarily be accounted for by body weight. This highlights that differences in pharmacokinetic parameters observed between groups in pharmacogenomic and disease state studies (or any clinical trial with a parallel study design) should be accompanied with the understanding that V_{ss} could differ significantly between groups. Therefore, although changes in AUC and CL between groups indicate meaningful differences, terminal halflife differences should be considered qualitative due to their dependence on the inherently variable V_{ss} value between individuals. Further, following oral dosing the changes in V_{ss}/F will reflect only changes in F for metabolic interactions. Therefore, this estimation of F change can subsequently be utilized to assess changes in CL alone from calculations of CL/F, two parameters that are considered indistinguishable from one another following oral dosing [3].

Acknowledgement: These findings were to be presented as a poster at the 2020 ASCPT Annual Meeting (March 18-21, 2020, Houston, TX), which was not held due to Covid-19, although the abstract (PII 142) was published, Sodhi et al., Clin Pharmacol Ther., 2020; 107 Supplement 1: S75.

Compliance with Ethical Standards:

Funding: This work was supported in part by a Mary Ann Koda-Kimble Seed Award for Innovation. Ms. Sodhi was supported in part by an American Foundation for Pharmaceutical Education Predoctoral Fellowship, NIGMS grant R25 GM56847 and a Louis Zeh Fellowship. Dr. Benet is a member of the UCSF Liver Center supported by NIH grant P30 DK026743

Conflicts of Interest: Authors report no conflicts of interest.

Ethical Approval: Not applicable

Informed Consent: Not applicable

References:

- 1. Grover A, Benet LZ. Effects of drug transporters on volume of distribution. AAPS J. 2009;11, 250-261.
- Benet LZ, Bowman CM, Sodhi, JK. How transporters have changed basic pharmacokinetic understanding. AAPS J. 2019;21:103.
- Sodhi JK, Benet LZ. A simple methodology to differentiate changes in bioavailability from changes in clearance following oral dosing of metabolized drugs. Clin Pharmacol Ther. 2020;[E-pub ahead of print, March 9, 2020].
- 4. Tornio A, Filppula AM, Niemi M, Backman JT. Clinical studies on drugdrug interactions involving metabolism and transport: methodology, pitfalls and interpretation. Clin Pharmacol Ther. 2019;105,1345-1361.
- Isoherranen N, Lutz JD, Chung SP, Hachad H, Levy RH, Ragueneau-Majlessi I. Importance of multi-P450 inhibition in drug-drug interactions: evidence of incidence, inhibition magnitude, and prediction from in vitro data. Chem Res Toxicol. 2012;25:2285-2300.
- Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic interactions with rifampicin. Clin Pharmacokinet. 2003;42:819-850.
- Pelkonen O, Mäeenpäeä J, Taavitsainen P, Rautio A, Paunio H. Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998;28:1203-1253.

- Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio
 H. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol. 2008;82:667-715.
- Polasek TM, Lin FPY, Miners JO, Doogue MP. Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment. Br J Clin Pharmacol. 2011;71:727-736.
- Bi Y, Mathialagan S, Tylaska L, Fu M, Keefer J, Vildede A, Costales C, Rodrigues AD, Varma MVS. Organic anion transporter 2 mediates hepatic uptake of tolbutamide, a CYP2C9 probe drug. J Pharmacol Exp Ther. 2018;364:390-398.
- Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol. 2005;97:249-256.
- Wu C-Y, Benet LZ. Predicting drug disposition via application of BCS: transport / absorption / elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22:11-23.
- Benet LZ, Galeazzi RL. Noncompartmental determination of the volume of distribution steady state. J Pharm Sci. 1979;68:1071-1074.Wahlländer A, Paumgartner G. Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. Eur J Clin Pharmacol. 1989;37:279-283.

- Leemann TD, Devi KP, Dayer P. Similar effect of oxidation deficiency (debrisoquine polymorphism) and quinidine on the apparent volume of distribution of (±)-metoprolol. Eur J Clin Pharmacol. 1993;45:65-71.
- Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM, Hall SD. The contribution of intestinal and hepatic CYP3A4 to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther. 1998;64:133-143.
- Quinney SK, Haehner BD, Rhoades MB, Lin Z, Gorski JC, Hall SD.
 Interaction between midazolam and clarithromycin in the elderly. Br J Clin Pharmacol. 2008;65:98-109.
- Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivarra L, Himberg
 JJ, Neuvonen PJ. A potentially hazardous interaction between
 erythromycin and midazolam. Clin Pharmacol Ther. 1993;53:298-305.
- Swart EL, van der Hoven B, Groeneveld ABJ, Touw DJ, Danhof M.
 Correlation between midazolam and lignocaine pharmacokinetics and MEGX formation in healthy volunteers. Br J Clin Pharmacol. 2002;53:133-139.
- 19. Kharasch ED, Walker A, Hoffer C, Sheffels P. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. J Clin Pharmacol. 2005;45:1187-1197.

- 20. Isoherranen N, Ludington SR, Givens RC, Lamba JK, Pusek SN, Dees EC, Blough DK, Iwanaga K, Hawke RL, Schuetz EG, Watkins PB, Thummel KE, Paine MF. The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitroin vivo evaluation. Drug Metab Dispos. 2008;36:146-154 (2008).
- 21. Olkkola KT, Ahonen J, Neuvonen PJ. The effect of systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg. 1996;82:511-516.
- Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ.
 Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. *Clin. Pharmacol. Ther.* 66: 461-471 (1999).
- 23. Shin K-H, Ahn LY, Choi MH, Moon J-Y, Lee J, Jang I-J, Yu K-S, Cho J-Y. Urinary 6β-hydroxycortisol/cortisol ratio most highly correlates with midazolam clearance under hepatic CYP3A inhibition and induction in females: a pharmacometabolomics approach. AAPS J. 2016;18:1254-1261.
- 24. Kirby BJ, Collier AC, Kharasch ED, Whittington D, Thummel KE, Unadkat JD. Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir. Drug Metab Dispos. 2011;38:1070-1078.

- 25. Loi C-M, Parker BM, Cusak BJ, Vestal RE. Aging and drug interactions. III. Individual and combined effects of cimetidine and ciprofloxacin on theophylline metabolism in healthy male and female nonsmokers. J Pharmacol Exp Ther. 1997;280:627-637.
- Breen KJ, Bury R, Desmond MB, Mashford MB, Morphett B,
 Westwood B, Shaw RG. Effects of cimetidine and ranitidine on hepatic drug metabolism. Clin Pharmacol Ther. 1982;31:297-300.
- Gugler R, Wolf M, Hansen H-H, Jensen JC. The inhibition of drug metabolism by cimetidine in patients with liver cirrhosis. Klin Wochenschr. 1984;62:1126-1131.
- Jackson JE, Powell JR, Wandell M, Bentley J, Dorr R. Cimetidine decreases theophylline clearance. Am Rev Respir Dis. 1981;123:615-617.
- Lin JH, Chremos AN, Chiou R, Yeh KC, Williams R. Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers. Br J Clin Pharmacol. 1987;24:669-672.
- Macias WL, Bergstrom RF, Cerimele BJ, Kassahun K, Tatum DE, Callagan JT. Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. Pharmacotherapy. 1998;18:1237-1248.
- 31. Bachmann K, Sullivan TJ, Reese JH, Jauregui L, Miller K, Scott M, Yeh KC, Stepanavage M, King JD, Schwartz J. Controlled study of the

putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease. J Clin Pharmacol. 1995;35:529-535.

- 32. Davis RL, Quenzer RW, Kelly HW, Powell JR. Effect of the addition of ciprofloxacin on theophylline pharmacokinetics in subjects inhibited by cimetidine. Ann Pharmacother. 1992;26:11-13.
- Prince RA, Casabar E, Adair CG, Wexler DB, Lettieri J, Kasik JE.
 Effect of quinolone antimicrobials on theophylline pharmacokinetics. J
 Clin Pharmacol. 1989;29:650-654. [2]
- 34. Abernethy DR, Egan JM, Dickinson TH, Carrum G. Substrateselective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans. J Pharmacol Exp Ther. 1988;224:994-999.
- 35. Sano M, Kawakatsu K, Ohkita C, Yamamoto I, Takeyama M, Yamashina H, Goto M. Effects of enoxacin, ofloxacin and norfloxacin on theophylline disposition in humans. Eur J Clin Pharmacol. 1988;35:161-165.
- 36. Stringer KA, Mallet J, Clarke M, Lindenfeld JA. The effect of three different oral doses of verapamil on the disposition of theophylline. Eur J Clin Pharmacol. 1992;43:35-38.
- 37. Nielsen-Kudsk JE, Buhl JS, Johannessen AC. Verapamil-induced inhibition of theophylline elimination in healthy humans. Pharmacol Toxicol. 1990;66:101-103.


- 38. Back DJ, Tjia J, Mönig H, Ohnhaus EE, Park BK. Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. Eur J Clin Pharmacol. 1988;34:157-163.
- Roberts RK, Grice J, Wood L, Petroff V, McGuffie C. Cimetidine impairs the elimination of theophylline and antipyrine.
 Gastroenterology. 1981;81:19-21.
- Ciraulo DA, Barnhill J, Boxenbaum H. Pharmacokinetic interaction of disulfiram and antidepressants. Am J Psychiatry. 1985;142:1373-1374.
- Cremer KF, Secor J, Speeg KV Jr. The effect of route of administration on the cimetidine-theophylline drug interaction. J Clin Pharmacol. 1989;29:451-456.
- Loi C-M, Parker BM, Cusack BJ, Vestal RE. Individual and combined effects of cimetidine and ciprofloxacin on theophylline metabolism in male nonsmokers. Br J Clin Pharmacol. 1993;36:195-200.
- Prince RA, Wing DS, Weinberger MM, Hendeles LS, Riegelman S.
 Effects of erythromycin on theophylline kinetics. J Allergy Clin Immunol.
 1981;68:427-431.
- Benet LZ, Bowman CM, Koleske ML, Rinaldi CL, Sodhi JK.
 Understanding drug-drug interaction and pharmacogenomic changes in pharmacokinetics for metabolized drugs. J Pharmacokinet
 Pharmacodyn. 2019;42:155-163.

Figure Legends:

Figure 1: Box plot depictions of the absolute magnitude of change in victim drug exposure (*AUC*) and volume of distribution at steady state (V_{ss}) expressed as ratios of interaction to control for (A) all drug-drug interactions (n=72) and (B) the subset of these interactions that are potentially clinically significant (with absolute *AUC* ratios > 1.3; n=49). The box indicates the median, 25th and 75th percentiles, the whiskers range from minimum to maximum values, and each individual data point is also depicted.

Figure 2: Ratios of change in (A) mean residence time (*MRT*) and (B) terminal half-life ($t_{1/2,z}$) compared with the inverse of change in clearance (*CL*). Red line indicates the line of unity.

Figure 1.






Table 1: Enzyme Specificities of Clinical Index Substrates andAdditional Victim Drugs

Substrate	BDDC S Class	Enzyme	Other Relevant Enzymes / Transporters	Referen ce
Antipyrine	1	CYP1A2 CYP2C9 CYP3A	Multiple CYPs (2A6, 2B6, 2C, 2E1)	[7]
Alfentanil	1	СҮРЗА	-	[5]
Caffeine	1	CYP1A2	Xanthine Oxidase N-Acetyl Transferase	[4]
Desipramine	1	CYP2D6	СҮРЗА	[4]
Imipramine	1	CYP2C19	CYP2D6	[5]
Lidocaine	1	CYP3A	CYP1A2	[7]
Metoprolol	1	CYP2D6	CYP3A	[4]
Midazolam	1	CYP3A	-	[4]
Theophylline	1	CYP1A2	CYP2E1 CYP3A	[4]
Tolbutamide	2	CYP2C9	OAT2	[4, 10]

Abbreviations: BDDCS, Biopharmaceutics Drug Disposition Classification System; CYP, Cytochrome P450; OAT, Organic Anion Transporter

Table 2: Inhibitory Specificities of Clinical Index Inhibitors andAdditional Perpetrator Drugs

Index Inhibitor	BDDCS Class	Enzyme	Other Relevant Enzymes / Transporters	Referen ce
Cimetidine	3	OCT2 CYP2C19 CYP3A	MATE1 CYP1A2 CYP2C9 CYP2D6	[5]
Ciprofloxacin	4	CYP1A2	CYP3A4	[4]
Clarithromycin	3	CYP3A4	CYP2C19 P-gp	[4]
Diltiazem	1	CYP3A4	CYP1A2 CYP2D6 P-gp	[5]
Disulfiram	2	CYP2E1	CYP1A2 CYP2C9 CYP2D6	[5]
Enoxacin	4	CYP1A2		[4]
Erythromycin	4	CYP3A4	P-gp	[4]
Famotidine	3	Unknown		
Fluconazole	3	CYP2C9 CYP2C19	CYP3A4	[4]
Itraconazole	2	CYP3A4	CYP2J2 P-gp	[4]
Ketoconazole	2	CYP3A4	CYP2C19 P-gp	[4]
Lidocaine	1	CYP3A4	CYP1A2	[7]
Nalidixic Acid	2	Unknown		
Nelfinavir	2	CYP3A4	CYP2D6	[8]
Norfloxacin	4	CYP1A2		[9]
Ofloxacin	3	Unknown		
Olanzapine	2	Unknown		
Ondansetron	1	Unknown		
Primaquine	1	Unknown		F 4]
Quinidine	1	CYP2D6	P-gp	[4]
Ranitidine	3	OCT2 CYP3A	CYP2C9 CYP2D6	[5]
Rifampin (Single Dose)	2	OATPs	CYP3A4	[6, 11]
Rifampin (Multiple Dose)	2	(Inducer) CYP3A CYP2C9 P-gp	(Inducer) CYP1A CYP2B6 CYP2C8 CYP2C19	[6]
Ritonavir (Single Dose)	2	CYP3A4	P-gp	[4]
Ritonavir (Multiple Dose)	2	CYP Induction		[4]
Sulfaphenazole	1	CYP2C9		[8]
Terbinafine	2	CYP2D6	CYP1A2	[4]
Verapamil	1	CYP3A4	P-gp	[4]

Abbreviations: BDDCS, Biopharmaceutics Drug Disposition Classification System; CYP, Cyotochrome P450; MATE, Multidrug and Toxic Extrusion; OCT, Organic Cation Transporter; P-gp, P-glycoprotein;

Victim	Perpetrator	Victim Enzymes or Transpor ters	Perpetra tor Enzymes or Transpor ters	Population	N	$\frac{AUC^{DD}}{AUC^{Cor}}$	CL ^{DDI}	$\frac{V_{ss}^{DDI}}{V_{ss}^{Con}}$	MRT ^{DDI} MRT ^{Cor}		Percent <i>AUC</i> Extrapolat ion
Caffeine	Ketoconazole (400 mg; Single Dose)	CYP1A2 NAT XO	CYP3A4 CYP2C19 P-gp	Healthy Subjects	8	1.17 ^b	0.88 ^b	0.97ª	1.14ª	1.18 ^b	36%/30%ª
Caffeine	Terbinafine (500 mg; Single Dose)	CYP1A2 NAT XO	CYP2D6 CYP1A2	Healthy Subjects	8	1.31 ^b	0.81 ^b	1.05ª	1.48ª	1.35 ^b	45%/30%ª
Metoprolo I	Quinidine (50 mg; Single Dose)	CYP2D6 CYP3A4	CYP2D6 P-gp	Healthy Subjects, Male, White, CYP2D6 Extensive Metabolizers	3	2.43 ^d	0.44 ^b	0.87 ^b	2.06 ^f	1.56ª	29%/15%ª
Metoprolo I	Quinidine (250 mg BID; 3 Days)	CYP2D6 CYP3A4	CYP2D6 P-gp	Healthy, Male, White, CYP2D6 Extensive Metabolizers	4	3.08 ^d	0.36 ^b	0.70 ^b	1.99 ^f	2.36ª	44%/15%ª
Metoprolo I	Quinidine (50 mg; Single Dose)	CYP2D6 CYP3A4	CYP2D6 P-gp	Healthy, Male, White, CYP2D6 Poor Metabolizers	3	1.12 ^d	0.98 ^b	1.18 ^b	1.30 ^f	1.09ª	35%/34%ª
Metoprolo I	Quinidine (250 mg BID; 3 Days)	CYP2D6 CYP3A4	CYP2D6 P-gp	Healthy, Male, White, CYP2D6 Poor Metabolizers	3	1.26 ^d	0.88 ^b	1.26 ^b	1.39 ^f	1.32ª	43%/34%ª
Midazola m	Clarithromycin (500 mg BID; 7 Days)	CYP3A4	CYP3A4 CYP2C19 P-gp	Healthy Subjects	16	2.66	0.37	1.05ª	2.79ª	2.66	38%/12%ª
Midazola m	Clarithromycin (500 mg BID; 7 Days)	CYP3A4	CYP3A4 CYP2C19 P-gp	Healthy Subjects, Elderly	16	3.2	0.35	1.16ª	2.24ª	4.06	44%/20%ª
Midazola m	Erythromycin (500 mg TID; 7 Days)	СҮРЗА4	CYP3A4 P-gp	Healthy Subjects	6	2.17 ^c	0.46	1.40	3.03 ^e	1.77	NR
Midazola m	Erythromycin (500 mg QID; 5 Days) + Lidocaine (1 mg/kg; 2 Days)	_ CYP3A4	CYP3A4 P-gp CYP3A4 CYP1A2	Healthy Subjects		1.60 ^d	0.71 ^b	0.93ª	1.31ª	1.50 ^b	19%/13%ª
Midazola m	Fluconazole (100 mg; Single Dose)	СҮРЗА4	CYP3A4 CYP2C9 CYP2C19	4 9 Healthy Subjects 19		1.3	0.78	1.01ª	1.28ª	1.16	10%/7%
Midazola	Fluconazole	CYP3A4	CYP3A4	Healthy Subjects	12	1.4	0.68	1.10ª	1.68ª	1.20	11%/7%

Table 3: Intravenous Drug-Drug Interaction Studies of Cytochrome P450 Index Substrates

		T		Т	<u> </u>		т	Τ	т	T	1
m	(200 mg; Single Dose)		CYP2C9 CYP2C19			í'					
Midazola m	Fluconazole (400 mg; Single Dose)	CYP3A4	CYP3A4 CYP2C9 CYP2C19	Healthy Subjects	12	2.0	0.54	0.93ª	1.73ª	1.56	17%/7%
Midazola m	Fluconazole (400 mg; Single Dose)	CYP3A4	CYP3A4 CYP2C9 CYP2C19	Healthy Subjects; African American CYP3A5*1/*1	6	1.62 ^b	0.64 ^b	0.81ª	1.15ª	1.35 ^b	17%/14%ª
Midazola m	Fluconazole (400 mg; Single Dose)	CYP3A4	CYP3A4 CYP2C9 CYP2C19	Healthy Subjects; African American CYP3A5*1/*X	7	1.67 ^b	0.60 ^b	0.99ª	1.70ª	1.43 ^b	17%/8%ª
Midazola m	Fluconazole (400 mg; Single Dose)	CYP3A4	CYP3A4 CYP2C9 CYP2C19	Healthy Subjects; African American CYP3A5*X/*X	6	1.97 ^b	0.51 ^b	0.79ª	1.61ª	1.44 ^b	16%/8%ª
Midazola m	Fluconazole (400 mg, 1 Day; 200 mg QD, 5 Days)	CYP3A4	CYP3A4 CYP2C9 CYP2C19	Healthy Subjects	12	2.02°	0.49	0.92	1.85 ^e	1.52	1%/1%ª
Midazola m	Itraconazole (200 mg QD; 6 Days)	CYP3A4	CYP3A4 CYP2J2 P-gp	Healthy Subjects	12	3.22°	0.31	1.08	3.49 ^e	2.41	16%/1%ª
Midazola m	Ketoconazole (200 mg BID; 2 Days)	СҮРЗА4	CYP3A4 CYP2C19 P-gp	Healthy Subjects; White	9	5.1	0.21	1.20ª	5.97ª	4.12	22%/6%ª
Midazola m	Ketoconazole (400 mg QD; 4 Days)	СҮРЗА4	CYP3A4 CYP2C19 P-gp	Healthy Subjects; Korean; Female	12	4.61°	0.22	0.57 [♭]	4.61 ^b	1.98	2%/2% ^b
Midazola m*	Nelfinavir (1250 mg BID; 14 Days)	CYP3A4	CYP3A4 Inhibition and Induction	Healthy Subjects	16	1.83	0.57	0.79ª	1.22ª	1.41	2%/3%ª
Midazola m	Rifampin (induction) (600 mg QD; 10 Days)	CYP3A4	CYP3A4 Inhibition and Induction	Healthy Subjects; Korean; Female	12	0.48 ^c	2.07	1.01 ^b	0.50 ^b	0.74	2%/2% ^b
Midazola m*	Rifampin (induction) (600 mg QD; 14 Days)	CYP3A4	CYP3A4 Inhibition and Induction	Healthy Subjects	16	0.44	2.16	1.19ª	0.54ª	0.61	4%/3%ª
Midazola m*	Ritonavir (600 mg TID, 1 Day; 300 mg BID, 6 Days; 400 mg BID, 7	СҮРЗА4	CYP3A4 Inhibition and Induction	Healthy Subjects	16	3.31	0.29	1.04ª	3.22ª	2.85	21%/3%ª

	Days)	T	Γ	T	· · · · · ·			Τ	T	T	1
Theophylli ne	Cimetidine (400 mg BID; 7 Days)	CYP1A2 CYP3A4 CYP2E1	CYP Enzymes OCT2 MATE1	Healthy; Young Men	8	1.31 ^c	0.77	1.10	1.44 ^e	1.41	NR
Theophylli ne	Cimetidine (400 mg BID; 7 Days)	CYP1A2 CYP3A4 CYP2E1	CYP Enzymes OCT2 MATE1	Healthy; Young Women	8	1.42 ^c	0.71	1.05	1.48 ^e	1.43	NR
Theophylli ne	Cimetidine (400 mg BID; 7 Days)	CYP1A2 CYP3A4 CYP2E1	CYP Enzymes OCT2 MATE1	Healthy; Elderly Men	8	1.36 ^c	0.73	0.98	1.34 ^e	1.31	NR
Theophylli ne	Cimetidine (400 mg BID; 7 Days)	CYP1A2 CYP3A4 CYP2E1	CYP Enzymes OCT2 MATE1	Healthy; Elderly Women	8	1.33 ^c	0.75	1.08	1.43 ^e	1.36	NR
Theophylli ne	Cimetidine (1000 mg BD; 7 Days)	CYP1A2 CYP3A4 CYP2E1	CYP Enzymes OCT2 MATE1	Healthy Subjects	7	1.56 ^d	0.66 ^b	1.02 ^b	1.58 ^f	1.84 ^b	NR
Theophylli ne	Cimetidine (1000 mg QD; 8 Days)	CYP1A2 CYP3A4 CYP2E1	CYP Enzymes OCT2 MATE1	Healthy Subjects	9	1.33 ^c	0.75	1.13 ⁹	1.83 ⁹	1.24	19%/5% ^g
Theophylli ne	Cimetidine (1000 mg QD; 8 Days)	CYP1A2 CYP3A4 CYP2E1	CYP Enzymes OCT2 MATE1	Liver Cirrhosis Patients	9	1.22 ^c	0.82	0.97 ⁹	1.36 ⁹	1.66	15%/9% ^g
Theophylli ne	Cimetidine (300 mg QID; 2.75 Days)	CYP1A2 CYP3A4 CYP2E1	CYP Enzymes OCT2 MATE1	Healthy Subjects; Males	5	1.69 ^d	0.61	1.11 ^h	1.90 ^h	1.73	32%/13% ^h
Theophylli ne	Cimetidine (300 mg QID; 6 Days)	CYP1A2 CYP3A4 CYP2E1	CYP Enzymes OCT2 MATE1	Healthy Subjects	10	1.46 ^d	0.74 ^b	1.12ª	1.53ª	1.38 ^b	30%/17%ª
Theophylli ne	Cimetidine (400 mg TID; 9 Days)	CYP1A2 CYP3A4 CYP2E1	CYP Enzymes OCT2 MATE1	Healthy; Males	7**	1.42	0.73	1.02ª	1.30ª	1.38	13%/8%ª
Theophylli ne	Cimetidine*** (800 mg BID; 9.5	CYP1A2 CYP3A4	CYP Enzymes	Chronic Obstructive Pulmonary Disease	15	1.35 ^d	0.77 ^b	1.10 ^b	1.47 ^b	1.45 ^b	13%/6%ª

	Days)	CYP2E1	OCT2	(COPD) Patients							
Theophylli ne	Cimetidine (600 mg QID; 6 Days)	CYP1A2 CYP3A4 CYP2E1	MATE1 CYP Enzymes OCT2	Healthy Subjects	8	1.63	0.60	1.07	2.01	1.80	NR
Theophylli ne	Ciprofloxacin (500 mg BID; 6 Days)	CYP1A2 CYP3A4 CYP2E1	MATE1 CYP1A2 CYP3A4	Healthy Subjects	8	1.43	0.69	1.04	1.70	1.51	NR
Theophylli ne	Ciprofloxacin (500 mg BID; 7 Days)	CYP1A2 CYP3A4 CYP2E1	CYP1A2 CYP3A4	Healthy Subjects; Males	8	1.34 ^d	0.76 ^b	1.02	1.36 ^e	1.43 ^b	21%/12%ª
Theophylli ne	Ciprofloxacin (500 mg BID; 8 Days)	CYP1A2 CYP3A4 CYP2E1	CYP1A2 CYP3A4	Healthy; Young Men	8	1.49°	0.67	1.02	1.52 ^e	1.51	NR
Theophylli ne	Ciprofloxacin (500 mg BID; 8 Days)	CYP1A2 CYP3A4 CYP2E1	CYP1A2 CYP3A4	Healthy; Young Women	8	1.50°	0.67	1.02	1.53 ^e	1.48	NR
Theophylli ne	Ciprofloxacin (500 mg BID; 8 Days)	CYP1A2 CYP3A4 CYP2E1	CYP1A2 CYP3A4	Healthy; Elderly Men	8	1.42 ^c	0.71	1.04	1.47 ^e	1.40	NR
Theophylli ne	Ciprofloxacin (500 mg BID; 8 Days)	CYP1A2 CYP3A4 CYP2E1	CYP1A2 CYP3A4	Healthy; Elderly Women	8	1.40°	0.71	1.08	1.51 ^e	1.45	NR
Theophylli	Ciprofloxacin (500 mg BID; 6 Days)	CYP1A2	CYP1A2 CYP3A4								
ne	+ Cimetidine (600 mg QID; 6 Days)	CYP3A4 CYP2E1	CYP Enzymes OCT2 MATE1	Healthy Subjects	8	1.80	0.55	1.11	2.26	2.03	NR
Theophylli	Ciprofloxacin (500 mg BID; 15 Days)	CYP1A2	CYP1A2 CYP3A4								
ne	+ Cimetidine (400 mg BID; 8 Days)	CYP3A4 CYP2E1	CYP Enzymes OCT2 MATE1	Healthy; Young Men	8	1.64 ^c	0.61	1.08	1.78 ^e	1.73	NR
Theophylli ne	Ciprofloxacin (500 mg BID; 15 Days)	CYP1A2 CYP3A4 CYP2E1	CYP1A2 CYP3A4	Healthy; Young Women	8	1.79 ^c	0.56	1.02	1.84 ^e	1.75	NR
	+ Cimetidine (400 mg BID; 8		CYP Enzymes]							

				1	-				-		
	Days)		OCT2 MATE1								
Theophylli	Ciprofloxacin (500 mg BID; 15 Days)	CYP1A2	CYP1A2 CYP3A4								
ne	+ Cimetidine (400 mg BID; 8 Days)	CYP3A4 CYP2E1	CYP Enzymes OCT2 MATE1	Healthy; Elderly Men	8	1.64 ^c	0.61	1.00	1.64 ^e	1.64	NR
Theophylli	Ciprofloxacin (500 mg BID; 15 Days)	CYP1A2	CYP1A2 CYP3A4	Healthy; Elderly							
ne	+ Cimetidine (400 mg BID; 8 Days)	CYP3A4 CYP2E1	CYP Enzymes OCT2 MATE1	Women	8	1.60°	0.63	1.08	1.72 ^e	1.68	NR
Theophylli ne	Diltiazem (120 mg TID; 6 Days)	CYP1A2 CYP3A4 CYP2E1	CYP3A4 CYP1A2 CYP2D6 P-gp	Healthy Subjects	10	1.02°	0.98	1.11 ⁹	1.01º	1.06	9%/9%ª
Theophylli ne	Enoxacin (200 mg TID; 3 Days)	CYP1A2 CYP3A4 CYP2E1	CYP1A2	Healthy Subjects	5	2.00 ^c	0.50	1.09ª	2.35ª	2.12	33%/7%ª
Theophylli ne	Famotidine (40 mg BID; 6 Days)	CYP1A2 CYP3A4 CYP2E1	Unknown	Healthy Subjects	10	0.95 ^d	1.07 ^b	1.12ª	1.06ª	1.08 ^b	17%/16%ª
Theophylli ne	Famotidine ^{***} (40 mg BID; 9.5 Days)	CYP1A2 CYP3A4 CYP2E1	Unknown	Chronic Obstructive Pulmonary Disease (COPD) Patients	15	0.99 ^d	1.02 ^b	1.03 ^b	1.02 ^b	1.02 ^b	6%/6%ª
Theophylli ne	Nalidixic Acid (500 mg QID; 7 Days)	CYP1A2 CYP3A4 CYP2E1	Unknown	Healthy Subjects; Males	8	0.99 ^d	1.04 ^b	1.04	1.02 ^e	1.12 ^b	NR
Theophylli ne	Norfloxacin (200 mg TID; 3 Days)	CYP1A2 CYP3A4 CYP2E1	CYP1A2	Healthy Subjects	5	1.08 ^c	0.93	1.11ª	1.29ª	1.17	13%/7%ª
Theophylli ne	Norfloxacin (400 mg BID; 7 Days)	CYP1A2 CYP3A4 CYP2E1	CYP1A2	Healthy Subjects; Males	8	1.17 ^d	0.86 ^b	1.02	1.19 ^e	1.24 ^b	18%/12%ª
Theophylli ne	Ofloxacin (200 mg TID; 3 Days)	CYP1A2 CYP3A4 CYP2E1	Unknown	Healthy Subjects	5	1.00°	1.00	1.08ª	1.11ª	1.06	10%/7%ª
Theophylli ne	Olanzapine (5 mg 1 Day;	CYP1A2 CYP3A4	Unknown	Healthy; Males	12	0.94	1.04	1.08ª	1.01ª	1.02	7%/7%ª

r			1	1							ı ———
	7.5 mg 1 Day; 10 mg QD 7 Days)	CYP2E1									
Theophylli ne	Ranitidine (150 mg BID; 7 Days)	CYP1A2 CYP3A4 CYP2E1	CYP3A CYP2C9 CYP2D6 OCT2	Healthy Subjects	7	1.21 ^d	0.92 [⊳]	0.97 ^b	1.16 ^f	1.28 ^b	NR
Theophylli ne	Verapamil (40 mg TID; 4 Days)	CYP1A2 CYP3A4 CYP2E1	CYP3A4 P-gp	Healthy Subjects, Male, White	12	1.13	0.92	0.98	1.06 ^e	1.11	15%/11%ª
Theophylli ne	Verapamil (80 mg TID; 4 Days)	CYP1A2 CYP3A4 CYP2E1	CYP3A4 P-gp	Healthy Subjects, Male, White	12	1.19	0.86	0.95	1.11 ^e	1.11	16%/11%ª
Theophylli ne	Verapamil (120 mg TID; 4 Days)	CYP1A2 CYP3A4 CYP2E1	CYP3A4 P-gp	Healthy Subjects, Male, White	12	1.28	0.82	0.90	1.10 ^e	1.25	18%/11%ª
Theophylli ne	Verapamil (120 mg TID; 8 Days)	CYP1A2 CYP3A4 CYP2E1	CYP3A4 P-gp	Healthy Subjects	7	1.25 ^d	0.81 ^b	0.97 ^b	1.21 ^f	1.22 ^b	45%/37% ⁹
Theophylli ne	Verapamil (120 mg QID; 6 Days)	CYP1A2 CYP3A4 CYP2E1	CYP3A4 P-gp	Healthy Subjects	10	1.29°	0.77	0.98 ⁹	1.31 ⁹	1.33	6%/3% ^g
Tolbutami de	Cimetidine (1000 mg QD, 4 Days; 600 mg 1 Day)	CYP2C9	CYP Enzymes OCT2 MATE1	Healthy	6	1.15°	0.87	1.01ª	1.19ª	1.13	4%/2%ª
Tolbutami de	Cimetidine (400 mg QID; 4.5 Days)	CYP2C9	CYP Enzymes OCT2 MATE1	Healthy	6	1.53°	0.65	0.96ª	1.46ª	1.46	5%/2%ª
Tolbutami de	Primaquine (45 mg; Single Dose)	CYP2C9	Unknown	Healthy	6	1.04 ^c	0.96	0.82ª	0.89ª	0.90	2%/4%ª
Tolbutami de	Sulfaphenazole (500 mg BID; 3.5 Days)	CYP2C9	CYP2C9	Healthy	7	3.10 ^c	0.32	0.86ª	3.21ª	3.07	26%/4%ª

Pharmacokinetic values reported in the table are based on published average values, unless otherwise noted

Abbreviations: *AUC*, area under the curve; *CL*, clearance; Con, control; CYP, cytochrome P450; DDI, drugdrug interaction; MATE1, Multidrug and Toxic Extrusion 1; *MRT*, Mean Residence Time; NAT, N, number of subjects; N-acetyl transferase; NR, not reported; OCT, organic cation transporter; P-gp, P-glycoprotein; REF, references; $t_{1/2,z}$, terminal half-life; V_{ss} , volume of distribution at steady state; XO, xanthine oxidase *Midazolam was dosed IV at the same time as a PO probe cocktail of tolbutamide, dextromethorphan and caffeine

**Interaction arm included n=7 subjects, however the control arm is only n=6 due to one subject dropping out of the study

***A list of additional drugs being taken by these chronic obstructive pulmonary disease subjects can be found in the original article by Bachmann et al. [32]

^aRatios are calculated by digitization of published average plasma concentration-time profiles and performing non-compartmental analysis

^bRatios are calculated for each individual using published individual PK data; the reported value reflects the average of each individual ratio

^cAUC was calculated with the equation AUC = dose / CL using known dose and reported average values of CL

^dAUC was calculated for each individual with the equation AUC = dose / CL using known dose and reported individual values of CL; the reported value reflects the average of each individual ratio

^eMRT was calculated with the equation $V_{ss} = CL \cdot MRT$ using reported average values of CL and V_{ss}

^fMRT was calculated for each individual with the equation $V_{ss} = CL \cdot MRT$ using reported individual values of CL and V_{ss} ; the reported value reflects the average of each individual ratio

⁹Ratios are calculated by digitization of a published plasma concentration-time profile of a single representative subject, which may not be reflective of all subjects in the study

^hRatios are calculated by digitization of individual published plasma concentration-time profiles and performing non-compartmental analysis; the reported value reflects the average of each individual ratio

Table 4: Intravenous Drug-Drug Interaction Studies with Additional Substrates (NotCytochrome P450 Index Substrates)

Victim	Perpetrator	Victim Enzymes or Transpor ters	Perpetra tor Enzymes or Transpor ters	Population	N	AUC ^{DDI} AUC ^{Cor}		$\frac{V_{ss}^{DDI}}{V_{ss}^{Con}}$	MRT ^{DD.} MRT ^{Con}		Percent <i>AUC</i> Extrapolat ion
Alfentanil	Fluconazole	CYP3A4	CYP3A4	Healthy Subjects	12	1.2	0.84	0.93ª	1.18ª	1.18	2%/1%

		τ									r
	(100 mg; Single Dose)		CYP2C9 CYP2C19								
l	+ Ondansetron	1	Unknown	1							
	(4 mg; Single Dose) + Midazolam	4		-		1					
	(1 mg; Single Dose)		Unknown								
	Fluconazole		CYP3A4			1					
	(200 mg; Single Dose)	1	CYP2C9 CYP2C19			1					
Alfentanil	+ Ondansetron (4 mg; Single Dose)	СҮРЗА4	Unknown	Healthy Subjects	12	1.6	0.62	0.89ª	1.45ª	1.36	3%/1%
	+ Midazolam (1 mg; Single Dose)		Unknown								
	Fluconazole (400 mg; Single Dose)		CYP3A4 CYP2C9 CYP2C19								
Alfentanil	+ Ondansetron (4 mg; Single Dose)	CYP3A4	Unknown	Healthy Subjects	12	2.2	0.46	0.90ª	1.92ª	1.73	5%/1%
	+ Midazolam (1 mg; Single Dose)		Unknown								
Antipyrin e	Cimetidine (1000 mg BD; 7 Days)	CYP Enzymes	CYP Enzymes OCT2 MATE1	Healthy Subjects	7	1.33 ^d	0.76 ^b	1.05 ^b	1.40 ^f	1.30 ^b	NR
Antipyrin e	Ranitidine (150 mg BID; 7 Days)	CYP Enzymes	CYP3A CYP2C9 CYP2D6 OCT2	Healthy Subjects	7	1.08 ^d	0.93 [⊳]	1.02 ^b	1.09 ^f	1.06 ^b	NR
Lidocaine	Erythromycin (500 mg QID; 5 days)	СҮРЗА4	CYP3A4 P-gp	Healthy Subjects	8	1.19 ^d	0.96 ^b	1.14ª	1.19ª	1.37 ^b	28%/23%ª
LIGOCAINE	+Midazolam (0.075 mg/kg; Single Dose)	CYP1A2	Unknown		0	1.19	0.90	1.14	1.19	1.57	2870/2370

Pharmacokinetic values reported in the table are based on published average values, unless otherwise noted

Abbreviations: *AUC*, area under the curve; *CL*, clearance; Con, control; CYP, cytochrome P450; DDI, drugdrug interaction; MATE1, Multidrug and Toxic Extrusion 1; *MRT*, Mean Residence Time; N, number of subjects; NR, not reported; OCT, organic cation transporter; P-gp, P-glycoprotein; *REF*, references; $t_{1/2,z}$,terminal half-life; V_{ss} , volume of distribution at steady state ^aRatios are calculated by digitization of published average plasma concentration-time profiles and performing non-compartmental analysis

^bRatios are calculated for each individual using published individual PK data; the reported value reflects the average of each individual ratio

^dAUC was calculated for each individual with the equation AUC = dose / CL using known dose and reported individual values of CL; the reported value reflects the average of each individual ratio

^fMRT was calculated for each individual with the equation $V_{ss} = CL \cdot MRT$ using reported individual values of CL and V_{ss} ; the reported value reflects the average of each individual ratio

	Find Drug meet			at only hepoirt it					<u>,</u>	- 21	
Victim	Perpetrator	Victim Enzymes or Transpor ters	Perpetra tor Enzymes or Transpor ters	Population	N	$\frac{AUC^{DD}}{AUC^{Cor}}$	$\frac{CL^{DDI}}{CL^{Con}}$	$\frac{V_z^{DDI}}{V_z^{Con}}$	MRT ^{DD.} MRT ^{Cor}		Percent <i>AUC</i> Extrapolat ion
Antipyrine	Cimetidine (1000 QD; 10 Days)	CYP1A2 CYP2C9 CYP3A4	CYP Enzymes OCT2 MATE1	Healthy Subjects	7	1.41	0.79	1.24	NR	1.59	NR
Desiprami ne	Disulfiram (500 mg QD; 31 Days)	CYP2D6 CYP3A4	CYP2E1 CYP1A2 CYP2C9 CYP2D6	Healthy Subject; Male	1	1.32	0.76	0.93	NR	1.20	NR
Imipramin e	Disulfiram (500 mg QD; 14 Days)	CYP2C19 CYP2D6	CYP2E1 CYP1A2 CYP2C9 CYP2D6	Healthy Subjects; Male	2	1.30 ^b	0.77 ^b	0.89 ^b	NR	1.16 ^b	NR
Theophylli ne	Cimetidine (300 mg PO QID; 1.5 Days)	CYP1A2 CYP3A4 CYP2E1	CYP Enzymes OCT2 MATE1	Healthy Subjects; Male	10	1.27 ^c	0.79	1.00	NR	1.24	NR
Theophylli ne	Cimetidine (300 mg IV Infusion QID; 1.5 Days)	CYP1A2 CYP3A4 CYP2E1	CYP Enzymes OCT MATE1	Healthy Subjects; Male	10	1.21 ^c	0.83	1.02	NR	1.20	NR
Theophylli ne	Cimetidine (400 mg BID; 7 Days)	CYP1A2 CYP3A4 CYP2E1	CYP Enzymes OCT MATE1	Healthy Subjects; Male	6	1.34 ^c	0.74	1.04	NR	1.42	NR
Theophylli ne	Cimetidine (1000 QD; 10 Days)	CYP1A2 CYP3A4 CYP2E1	CYP Enzymes OCT MATE1	Healthy Subjects	7	1.10	0.90	1.04	NR	1.15	NR
Theophylli ne	Ciprofloxacin (500 mg BID; 7 Days)	CYP1A2 CYP3A4 CYP2E1	CYP1A2 CYP3A4	Healthy Subjects; Male	6	1.48°	0.68	1.00	NR	1.47	NR
Theophylli ne	Ciprofloxacin (400 mg BID; 7 Days) + Cimetidine	CYP1A2 CYP3A4 CYP2E1	CYP1A2 CYP3A4 CYP	Healthy Subjects; Male	6	1.70 ^c	0.59	1.00	NR	1.78	NR
	(500 mg BID; 7		Enzymes	′							

Table 5: Drug-Drug Interaction Studies that only Report Terminal Volume of Distribution (Vz)

	Days)		OCT2 MATE1								
Theophylli ne	Erythromycin (250 mg QID; 7 Days)	CYP1A2 CYP3A4 CYP2E1	CYP3A4 P-gp	Healthy Subjects; Male	8	1.38 ^c	0.74 ^b	0.92 ^b	NR	1.27 ^b	NR

Pharmacokinetic values reported in the table are based on published average values, unless otherwise noted

Abbreviations: *AUC*, area under the curve; *CL*, clearance; Con, control; DDI, drug-drug interaction; MATE1, Multidrug and Toxic Extrusion 1; *MRT*, Mean Residence Time; N, number of subjects; NR, not reported, OCT, organic cation transporter; *REF*, references; $t_{1/2,z}$, terminal half-life; V_z , terminal volume of distribution ^bRatios are calculated for each individual using published individual PK data; the reported value reflects the average of each individual ratio

^cAUC was calculated with the equation AUC = dose / CL using known dose and reported average values of CL

Table 6: Intravenous Pharmacogenomic Interaction Studies and Disease State Drug-Drug Interaction Studies

Drug	Enzy me	Population	N	AUC ^{∫i} AUC ^{Con} i	$\frac{CL^{\int i}}{CL^{Con}} i$	$\frac{V_{ss}^{\int i}}{V_{ss}^{Con}}i$	$\frac{MRT^{\int i}}{MRT^{Con}}i$	$\frac{t_{1/2,z}^{\int i}}{t_{1/2,z}^{Con}}i$	Percent AUC Extrapolat ion	REF
Motoprolo	СҮР2	Control : Healthy Subjects, White, Male, CYP2D6 Extensive Metabolizers; 58-80 kg	3	2.56°	0.40	0.51	1.29 ^e	1.81ª	34%/15%ª	[15]
Metoprolol	D6	Phenotype: Healthy Subjects, White, Male, CYP2D6 Poor Metabolizers; 65-86 kg	4	2.50*	0.40	0.51	1.29	1.01	54%/15%	[15]
Midazolam	СҮРЗ	Control: Healthy Subjects, African American, CYP3A5*1/*1; 57-97 kg for all subjects	6	0.98	1.04	0.79ª	0.70ª	0.93	8%/14%ª	[21]
Midazolam	A	Phenotype: Healthy Subjects, African- American, CYP3A5*1/*X; 57-97 kg for all subjects	7	0.98	1.04	0.79	0.70	0.95	8 /0/ 14 /0	[21]
Midazolam	СҮРЗ	Control: Healthy Subjects, African American, CYP3A5*1/*1; 57-97 kg for all subjects	6	1.05	0.99	0.72ª	0.70ª	0.96	8%/14%ª	[21]
Mudzolam	A	Phenotype: Healthy Subjects, African- American, CYP3A5*1/*X; 57-97 kg for all subjects	6	1.05	0.99	0.72	0.70	0.90	8 %/ 14 %	[21]
	CYP1 A2	Control: Healthy Subjects; average weight 80.7 kg	9							
Theophyllin e	CYP3 A4 CYP2E 1	Disease State: Liver Cirrhosis Patients; average weight 68.6 kg	9	1.54 ^c	0.65	0.70 ⁹	1.2 ^g	1.76	8%/14%ª	[28]

Pharmacokinetic values reported in the table are based on published average values, unless otherwise noted

Abbreviations: *AUC*, area under the curve; *CL*, clearance; Con, control (indicating the wild-type pharmacogenomic phenotype or healthy subject group); CYP, cytochrome P450; Int, interaction (indicating the reduced function pharmacogenomic phenotype or disease state group); *MRT*, Mean Residence Time; N, number; REF, references; $t_{1/2,z}$, terminal half-life; V_{ss} , volume of distribution at steady state

^aRatios are calculated by digitization of published average plasma concentration-time profiles and performing non-compartmental analysis

 ^{c}AUC was calculated with the equation AUC = dose / CL using known dose and reported average values of CL

^eMRT was calculated with the equation $V_{ss} = CL \cdot MRT$ using reported average values of CL and V_{ss} ^gRatios are calculated by digitization of a published plasma concentration-time profile of a single representative subject (one healthy subject and one liver cirrhosis patient), which may not be reflective of all subjects in the study Table 7: Utilization of the Sodhi and Benet Methodology [3] to Discriminate Clearance (CL) from Bioavailability (F) Changes for Orally Dosed Midazolam (Victim) and Clarithromycin (Perpetrator) from the Study of Quinney et al.[17]

Victim	Perpetrator	<u>AUC^{DDI}</u> AUC ^{Control}	Percent AUC Extrapola tion (DDI/ Control)	$\frac{V_{ss}/F^{DDI}}{V_{ss}/F^{Control}}$	$\frac{V_{ss}^{DDI}}{V_{ss}^{Control}}$	$\frac{F^{DDI}}{F^{Control}}$	<u>CL</u> /F ^{DDI} CL/F ^{Control}	<u>CL</u> ^{DDI} CL ^{Control}	REF
Midazolam (IV)	Clarithromycin (500 mg BID; 7 Days)	Observed: 3.2	Observed: 44% / 19%ª	_	Observed: 1.16ª	Observed: 2.12	-	Observe d: 0.35	[17]
¹⁵ N₃-Midazolam (Oral)	Clarithromycin (500 mg BID; 7 Days)	Observed: 8.2	Observed: 33% / 12%ª	Observed: 0.35ª	Assumed: 1	Estimated : 2.84 ^b	Observed: 0.14	Estimate d: 0.40 ^b	[17]

Pharmacokinetic values reported in the table are based on published average values, unless otherwise noted

Abbreviations: AUC, area under the curve; CL, clearance; DDI, drug-drug interaction; F, bioavailability; REF, reference; V_{ss} , volume of distribution at steady state

^aRatios are calculated by digitization of published average plasma concentration-time profiles and performing non-compartmental analysis

^bRatios are calculated for each individual using published individual PK data; the reported value reflects the average of each individual ratio